Stryker (SYK) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Stryker (NYSE:SYK) in a research report released on Wednesday morning.

“On 1/9/18, SYK preannounced 4Q17 revenue that was above consensus. Management refrained from providing 2018 guidance, however, and plans to provide this on its 4Q17 call on Tuesday, 1/30/18. Although there was no guidance, management did indicate that tax reform would create a modest headwind” to its earnings in 2018. SYK placed 35 Mako systems in 4Q17, which was up modestly from 33 in 3Q17 and 32 in 4Q16; SYK noted that Mako helped to drive 10.5% US knee growth in 4Q17. Clearly 4Q17 was another strong quarter for SYK but we maintain our Hold rating given its valuation (2018E P/E of 22.5x, which is approximately in line with its large-cap peers’ median of 22.9x).”,” Needham & Company LLC’s analyst wrote.

A number of other research analysts have also weighed in on the stock. JPMorgan Chase & Co. raised shares of Stryker from a neutral rating to an overweight rating in a research note on Tuesday, January 2nd. Robert W. Baird upgraded shares of Stryker from a neutral rating to an outperform rating and increased their target price for the company from $161.00 to $173.00 in a report on Thursday, November 16th. Zacks Investment Research downgraded shares of Stryker from a hold rating to a sell rating in a report on Monday, October 16th. BMO Capital Markets upgraded shares of Stryker to a market perform rating and set a $163.00 target price for the company in a report on Tuesday, December 12th. Finally, SunTrust Banks reiterated a buy rating and issued a $161.00 target price on shares of Stryker in a report on Friday, November 17th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Stryker has a consensus rating of Hold and a consensus target price of $156.60.

Stryker (SYK) traded up $0.01 during trading on Wednesday, hitting $160.28. 1,361,501 shares of the company’s stock were exchanged, compared to its average volume of 1,241,350. Stryker has a 12-month low of $119.17 and a 12-month high of $164.20. The company has a market capitalization of $59,980.00, a price-to-earnings ratio of 34.17, a price-to-earnings-growth ratio of 2.28 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same period last year, the firm earned $1.39 earnings per share. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. sell-side analysts forecast that Stryker will post 6.49 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, December 28th. This is an increase from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio (DPR) is 40.09%.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SYK. Beach Investment Management LLC. purchased a new stake in Stryker during the second quarter worth about $1,924,000. First National Trust Co. boosted its position in Stryker by 6.2% during the second quarter. First National Trust Co. now owns 9,625 shares of the medical technology company’s stock worth $1,336,000 after purchasing an additional 561 shares during the period. Victory Capital Management Inc. boosted its position in Stryker by 12.8% during the second quarter. Victory Capital Management Inc. now owns 19,892 shares of the medical technology company’s stock worth $2,761,000 after purchasing an additional 2,253 shares during the period. Aviva PLC boosted its position in Stryker by 2.6% during the second quarter. Aviva PLC now owns 209,048 shares of the medical technology company’s stock worth $29,014,000 after purchasing an additional 5,330 shares during the period. Finally, Blue Chip Partners Inc. boosted its position in Stryker by 0.3% during the second quarter. Blue Chip Partners Inc. now owns 1,781 shares of the medical technology company’s stock worth $247,000 after purchasing an additional 6 shares during the period. Institutional investors and hedge funds own 74.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Stryker (SYK) Given Hold Rating at Needham & Company LLC” was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://weekherald.com/2018/01/19/stryker-syk-given-hold-rating-at-needham-company-llc.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply